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The NF-kB signalling module controls transcription through a network of
protein kinases such as the IKKs, as well as inhibitory proteins (IkBs) and tran-
scription factors including RelA/p65. Phosphorylation of the NF-kB subunits
is critical for dictating system dynamics. Using both non-targeted discovery
and quantitative selected reaction monitoring-targeted proteomics, we show
that the cytokine TNFa induces dynamic multisite phosphorylation of RelA
at a number of previously unidentified residues. Putative roles for many of
these phosphorylation sites on RelA were predicted by modelling of various
crystal structures. Stoichiometry of phosphorylation determination of Ser45
and Ser42 revealed preferential early phosphorylation of Ser45 in response
to TNFa. Quantitative analyses subsequently confirmed differential roles for
pSer42 and pSer45 in promoter-specific DNA binding and a role for both of
these phosphosites in regulating transcription from the IL-6 promoter. These
temporal dynamics suggest that RelA-mediated transcription is likely to be
controlled by functionally distinct NF-kB proteoforms carrying different com-
binations of modifications, rather than a simple ‘one modification, one effect’
system.1. Introduction
The transcription factor RelA (also known as p65) is a key component of NF-kB
signalling. Upon dimerization, RelA regulates expression of a myriad of genes
underpinning diverse cellular processes, including inflammation, cell growth
and transformation. Impairment or dysregulation of the system has been
linked to many severe pathological states, including chronic inflammatory dis-
eases [1], autoimmune disorders [2] and cancer [3]. Like most signalling
pathways, the dynamics of NF-kB is precisely controlled by post-translational
modifications (PTMs), with phosphorylation playing a central rate-limiting
role in transcription [4–6]. Modification of approximately 25 different RelA
residues has been reported to date, although many have been annotated
solely following high-throughput mass spectrometric analysis [7] (www.
phosphosite.org [8]). Distinct phosphorylation events are known to modulate
RelA stability, nuclear localization and/or transcriptional activity by regulat-
ing binding to DNA and/or proteins [5]. It is now appreciated that the
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the so-called NF-kB code [9], are likely to be dependent on
both the context and activating stimulus, and the specific
cell type.
Elucidation of the mechanistic control of NF-kB signalling
outputs in response to specific extracellular signals requires
an understanding of the roles and interplay of a dense network
of coexisting RelA modifications. Most studies examining
covalent RelA modification evaluate select sites of interest,
often relying on mutagenesis or site-specific antibodies to
study individual sites. While these strategies have generated
much fundamental information, they fail to examine the com-
posite, biologically relevant picture of the dynamics and roles
of the different post-translationally modified forms (proteo-
forms) of the NF-kB complex. An in-depth investigation of
RelA phosphorylation under defined cellular conditions is
still lacking, yet such studies are essential to understand the
combinatorial role of different modifications. Crucially, this
lack of information significantly impairs our ability to model
the NF-kB system at levels approaching the natural complexity
found in vivo [10,11].
Mass spectrometry (MS) is the method of choice for PTM
characterization owing to its sensitivity and versatility, offering
unique advantages over other approaches. MS permits the
identification and quantification of modification sites even
under extremely challenging conditions, for example when
they occur with low stoichiometry or are located on low abun-
dance proteins such as transcription factors. However, the
substoichiometric nature of most PTM events reduces the
likelihood of their identification in a typical shotgun data-
dependent acquisition (DDA), where only the most abundant
peptide ions will yield sequence information. While these
types of experiments are extremely useful for discovery pur-
poses, more targeted approaches, often based on selected
reaction monitoring (SRM), improve detection and are optimal
for the quantification of (modified) peptides [12–14].
Cellular exposure to cytokines such as tumour necrosis
factor alpha (TNFa) induces IKK-mediated phosphorylation
of IkB, targeting it for degradation via the ubiquitin–
proteosome pathway (reviewed in [15]). Consequently, activated
NF-kB is no longer sequestered in the cytoplasm and can
translocate to the nucleus, where it regulates target gene
transcription. Prolonged stimulation with TNFa promotes
cell type-dependent sustained nuclear–cytoplasmic oscil-
lations of RelA with a typical period of approximately
100 min, regulated by negative feedback loops involving
the continual degradation and re-synthesis of IkB via the
‘canonical’ pathway [16–19]. Although RelA is known to be
phosphorylated on a number of residues following cytokine
stimulation, the lack of consistency in experimental design
makes understanding phosphosite dynamics, their coordi-
nated regulation and physiological functions nigh-on
impossible. Here, we exploit a combination of shotgun and
targeted MS strategies to define the temporal dynamics of
endogenous RelA phosphorylation in SK-N-AS neuroblas-
toma cells in response to TNFa exposure, identifying seven
novel phosphorylation sites on RelA (Ser42, Ser131, Thr136,
Ser238, Ser261, Ser269 and Ser472). Additionally, we charac-
terize a biologically relevant phosphosite (Ser45) only
previously annotated in high-throughput proteomic analyses.
Structural interrogation and cell-based analyses enable us to
confirm that two of these phosphorylation sites, Ser42 and
Ser45, regulate DNA binding and transcription. Furthermore,our data provide the first quantitative temporal fingerprint of
RelA phosphorylation dynamics, information that will be
vital to understand, model and ultimately selectively perturb
the NF-kB signalling module.2. Results
2.1. Endogenous RelA is dynamically phosphorylated
following cellular stimulation with TNFa
Our initial objective was to dissect dynamic (stimulation-
induced) regulation of RelA by PTMs. We first set out to
characterize the sites of modification on endogenous RelA
following exposure of human cells to the pro-inflammatory
cytokine TNFa. Preliminary analyses of a tryptic digest of
SK-N-AS cell extracts fractionated either by strong anion
exchange (36 fractions), high-pH reversed-phase (40 frac-
tions) or GeLC (40 slices from SDS–PAGE) [20] prior to
LC–MS/MS failed to identify RelA-derived tryptic peptides,
indicating that the endogenous transcription factor was
expressed at levels below the detection limit of the nano-
ESI-Orbitrap Velos system used, validated here to be in the
region of 120 000 protein copies (approx. 200 zeptomoles)
per cell [21], owing to limitations in the number of cells
that can be analysed in a single run. All subsequent investi-
gations thus relied on antibody-based enrichment of
endogenous RelA. LC–MS/MS analysis of tryptic peptides
derived from immunoprecipitated (IP’ed) RelA yielded 52%
sequence coverage, with peptides representing most of the
protein N-terminus (amino acids 42–314; figure 1), but lack-
ing coverage over the C-terminus. Of note for ‘bottom-up’
proteomics analysis and PTM discovery, much of the RelA
C-terminal region, which contains the transactivation
domains (TAs), lacks suitable Lys/Arg trypsin cleavage
sites. Indeed, in silico tryptic digestion of RelA predicts that
approximately 40% of theoretical peptides will not be
observed, primarily because the peptide fragments are too
large to elute from a standard C18 reverse-phase column.
Moreover, many of the potential tryptic cleavage sites are
either clustered in basic (e.g. KKK or KxKxK) or acidic (D/E
at positions P2, P10 and P20) motifs, which significantly
increase the likelihood of incomplete proteolysis [22–24].
Incomplete trypsin digestion of NF-kB proteins is further
complicated by extensive PTM, including Ser/Thr phos-
phorylation and Lys acetylation, both of which decrease
proteolytic efficiency [25]. To overcome this problem, alternate
site-specific proteases (chymotrypsin, elastase, GluC) were
employed, and these marginally increased protein sequence
coverage. When combined with tryptic digest information,
this led to the identification of nine sites of RelA phosphoryl-
ation after TiO2 phosphopeptide-enrichment, including six
novel sites: pSer42, pSer131, pThr136, pSer261, pSer269 and
pSer472 (figure 1 and electronic supplementary material,
table S1 and figure S1). In addition, the phosphorylation of
Ser45, a site previously reported in a single high-throughput
MS-based screen [26], was confirmed, and two known sites
of phosphorylation, pThr254 [27] and pSer468 [28–30], were
identified (electronic supplementary material, figure S1).
Interestingly, this extensive analysis still did not account
for several TNFa-induced phosphorylation sites on RelA
originally identified using non-MS-based approaches, includ-
ing pSer536 [29,31,32], most likely owing to an inability to
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Figure 1. TNFa induces dynamic multi-site phosphorylation of endogenous RelA. (a) Phosphorylation sites identified at 5, 20, 40, 60 min post-stimulation of SK-N-AS
cells with the cytokine TNFa are detailed. No phosphorylation sites were observed in the absence of stimulation. CID product ion spectra of a (b) doubly charged ion at
m/z 437.7, indicating phosphorylation of Ser42 and Ser45; (c) doubly charged ion at m/z 570.1, indicating phosphorylation of Ser131; (d ) triply charged ion at m/z 669.7,
indicating phosphorylation of Ser136; (e) doubly charged ion m/z 796.2, indicating phosphorylation of Ser261; ( f ) triply charged ion at m/z 769.2, indicating
phosphorylation of Ser269. (g) Schematic of RelA detailing known and novel (*) sites of modification. Phosphorylation sites are in red, glycosylation sites in green;
a, acetylation; m, methylation; n, nitrosylation; o, oxidation; u, ubiquitination; TA, transactivation domain. Dark grey blocks represent those regions in the primary
sequence identified by shotgun LC–MS/MS analysis following proteolytic cleavage with different enzymes.
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ditions. Although we interrogated the LC–MS data for
other types of PTM, including Cys oxidation, sulfhydration,nitrosylation, acetylation and methylation of Lys, Tyr nitrosy-
lation and ubiquitinylation [33–35], only a single acetylation
site at Lys303 was observed.
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Figure 2. In vitro site-specific RelA phosphorylation is significantly increased in the presence of IkBa and/or p50. The sites identified following in vitro phos-
phorylation of RelA with PKA or IKKb, either alone or in the presence of stoichiometric amounts of p50, or p50 and IkBa are detailed. (a) Qualitative
phosphosite identification following discovery LC–MS/MS. (b) Selected reaction monitoring (SRM) determined relative change in phosphopeptide level compared
with RelA alone. Statistical significance was assessed using a one-way ANOVA and a post hoc Tukey test; *p, 0.05, ***p , 0.001 with respect to RelA alone for
each site and kinase; ###p, 0.001 with respect to RelA : p50 for each site and kinase. N.B. Relative phosphorylation cannot be directly compared between phos-
phopeptides and thus phosphorylation sites owing to differences in peptide ionization efficiency.
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abrogated by IkBa
To help understand the regulation of RelA phosphorylation
using a biochemical approach and purified components,
LC–MS/MS was employed to map phosphorylation sites on
RelA (12–317) induced by the known NF-kB kinases IKKb
and the catalytic subunit of protein kinase A (PKA; figure 2)
[30,36]. In an attempt to mimic the RelA supramolecular
assemblies found in cells, phosphorylationwas also monitored
after inclusion of stoichiometric amounts of the IkBa and/or
p50 partner proteins (electronic supplementary material,
figures S1–S3). In addition to the discovery studies used to
pinpoint the residues phosphorylated under each of these con-
ditions, quantitative SRM assays were developed to assess
stoichiometry of phosphorylation of each of the sites, and
therefore determine the relative change in phosphorylation
upon inclusion of p50 and IkBa (figure 2 and electronic sup-
plementary material, table S2 and figure S3). SRM assays that
target specific peptide ions overcome the stochastic nature of
data-dependent MS-based proteomics, where lack of obser-
vation of a (phospho)peptide is not necessarily indicative of
its absence.
IKKb induced RelA phosphorylation on both the newly
identified Ser131 and at Ser311 (figure 2 and electronic sup-
plementary material, figure S3), a site previously reported to
be PKC-dependent [37,38]. Inclusion of p50, a key RelA hetero-
dimerization partner, increased levels of both pSer131 and
pSer311 by threefold and 1.6-fold, respectively. The increase
in phosphorylation at both sites was markedly reduced
(approx. 7- and 12.5-fold for Ser131 and Ser311, respectively)
upon inclusion of IkBawith the RelA : p50 complex. Likewise,
the PKA and/or IKKb-mediated phosphorylation of Ser238
was abrogated in the presence of p50 and IkBa.When evaluating relative phosphorylation at Ser45, it was
important to consider total amounts of both the singly
phosphorylated pSer45-containing, as well as the doubly phos-
phorylated Ser42/Ser45 peptides. IKKb phosphorylation of the
singlyphosphorylatedSer45RelApeptide increasedsignificantly
in the presence of p50, but there was a notable reduction in the
levels of this phosphopeptide upon addition of IkBa (figure 2).
When considering these data alongside the marked increase in
the levels of the doubly phosphorylated Ser42/Ser45-containing
peptide, it is apparent that phosphorylation of both Ser42 and
Ser45 is enhanced upon formation of the tertiary complex, equiv-
alent to approximately 60-fold over RelA alone. Like IKKb, PKA
phosphorylation of Ser42/Ser45 is significantly elevated in the
ternary complex of RelA : p50 : IkBa. However, unlike IKKb,
PKA favours phosphorylation of both Ser42 and Ser45 on RelA
for the RelA : p50 heterodimer. pSer45 is thus maximal in the
presence of p50 and IkBa, irrespective of the kinase used.
The levels of pSer261, pSer281 and pThr305, in addition to
pSer131 and pSer311, increased significantly in the presence of
p50 following IKKb incubation, but were reduced (or absent)
when co-incubated with IkBa. p50 thus promotes hyperpho-
sphorylation of RelA by IKKb, and to a lesser extent PKA, and
this is abrogated upon addition of the inhibitor IkBa protein.
Although only three (Ser205, Ser281 and Ser311) of the 13 phos-
phosites identified in our in vitro studies have previously been
described [36,37,39–41], four new in cellulo sites (Ser131,
Thr136, Ser261, Ser269) were validated in these biochemical
assays (electronic supplementary material, table S1).
2.3. Structural modelling predicts putative roles for
RelA phosphorylation sites
To assess functional conservation of RelA phosphosites in
vertebrates, a sequence alignment was performed. Of the
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and images are coloured as follows: RelA, yellow; p50, cyan; IkBa, orange; interface residues on RelA, red or blue; novel serine phosphorylation sites, yellow; known
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sequence (PDB ID: 1LEI—p50 removed for clarity).
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in vivo), nine residues (five of which have not previously
been described (in italics)) are completely conserved across
all species (Ser42, Ser45, Ser112, Thr136, Ser203, Ser205,
Thr254, Ser281, Thr305), as is the previously reported Ser276
(electronic supplementary material, figure S3). Ser238, Ser240
and Ser472 (and previously identified sites at Ser311, Ser468,
Thr505, Ser529, Ser536 and Ser547) are highly conserved in
most mammals, but exhibit reduced conservation in chicken,
frog and zebrafish. It is interesting to note that sequence con-
servation is considerably higher across the N-terminal RHD,
which regulates binding to proteins such as the NF-kB
subunits, when compared with the C-terminal TA domains.
Co-crystal structures of RelA in complex with p50, IkB
and/or DNA, including PDB IDs: 1NFI (RelA : p50 : IkBa)
[42], 1IKN (RelA : p50 : IkBa) [43], 1K3Z (RelA : IkBb) [44]
and 1LEI (RelA : p50 : DNA) [45] were employed to evaluate
potential roles of RelA phosphorylation on intermolecular
complex assembly. Notably Ser240, which lies at the interfacewith IkB (a/b), acts to stabilize the interaction of the complex
by formation of hydrogen bonds with either Arg260 (1IKN) or
Leu256 (1NFI) of IkBa (figure 3a,b). Phosphorylation at Ser240
is predicted to destabilize the interaction of RelAwith IkBa by
removing these interactions. Close proximity of Ser238 to resi-
dues regulating the interaction with IkBa through either
hydrogen bonds (Ser240, Gln241, Asp243) or a salt bridge
(Asp243) also supports a role for pSer238 in regulating the
interaction of RelA with IkBa. Furthermore, this modelling
supports our in vitro kinase assay data, where statistically
lower levels (0.7-fold) of IKKb-inducedpSer238 in the presence
of IkBa (figure 2) were measured. Likewise, phosphorylation
of RelA at Ser261, which also lies near the interface with
IkBa, was 2.1-fold higher in the absence of IkBa. Structural
comparison of both a RelA homodimer complexed with IkBb
(1K3Z [44] and figure 3c) and a RelA : p50 heterodimer with
IkBa suggests that pSer203 and pThr305 also are likely to regu-
late the RelA : IkB interaction. The interface between RelA, p50
and p105 lies +5 residues either side of Ser205 (figure 3d ),
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lating heterodimer formation. Of particular interest were Ser42
and Ser45, given that they appear to be directly involved in
the interaction of NF-kB with the kB DNA sequence
(figure 3e). We thus predicted a critical role for these sites in
regulating the DNA binding propensity of RelA.
2.4. Quantitative selected reaction monitoring-based
temporal profiling of Ser42 and Ser45
phosphorylation in response to TNFa
The DNA binding and transcriptional activity of NF-kB sub-
units is known to be dynamically regulated by reversible
covalent modifications [27–29,31,46–54]. Our observation
that, first, phosphorylation at Ser42 and Ser45 appears to be
temporally regulated in response to TNFa (figure 1), second
that both Ser42 and Ser45 are evolutionarily conserved (elec-
tronic supplementary material, figure S3) and third that
phosphorylation of one or both of these sites may structurally
regulate DNA binding (figure 3e) meant that defining and
quantifying TNFa-induced temporal dynamics of phosphoryl-
ation of these two residues was a priority. SRM, exploiting
isotope-labelled peptides as internal reference standards,
offers significant improvements in detection limits over the dis-
covery-type analyses used for early RelA phosphosite mapping
[14] and is ideally suited to quantitative temporal profiling.
Quantification by SRM is the ‘gold-standard’ in protein quanti-
fication and is significantly more robust than other commonly
exploited techniques such as western blotting [55].
We designed SRM assays for singly (pSer42 or pSer45)
and doubly phosphorylated (pSer42 and pSer45) forms of
the tryptic peptide (p)SAG(p)SIPGER, as well as the sequence
surrounding pSer276 (VSMQLRRPpSDR). SRM transitions
were also designed for a non-modified reference peptide
(DGFYEAELCPDR), whose quantitative profiling was used
to normalize for the total amount of IP’ed endogenous RelA
in the assays (figure 4a and electronic supplementary material,
figures S4 and S5). Phosphopeptide (and thus phosphosite)
quantification as a function of time following cell stimulation
was performed by monitoring the SRM signals (peak areas)
of the three phosphopeptides relative to the non-modified
RelA tryptic peptide. In order to define the absolute amounts
of each of the phosphopeptides, and thus the stoichiometry
of phosphorylation at each of the sites, known amounts
of identical [13C6] Arg peptides were included as internal
quantification standards.
Using this approach, quantitative changes in site-specific
RelA phosphorylation stoichiometry in cellulowere determined
for the first time. As well as confirming cellular phosphoryl-
ation of Ser238, we evaluated time-dependent pSer45,
pSer42pSer45 and pSer276 modification after TNFa exposure,
employing three independent biological replicates for analysis
(figure 4b–e). A series of co-eluting transitions specific for the
peptide phosphorylated at Ser45 (including y7–98) were
recorded, permitting discrimination between pSer42 and
pSer45 positional isomers and quantification of pSer45.
SRM-based quantification of endogenous RelA phos-
phorylation reveals rapid biphasic regulation of pSer42/45 in
response to TNFa stimulation (figure 4). Similar phosphoryl-
ation dynamics were also observed after immunoblotting
with a phospho-specific antibody raised against the dual
Ser42/45 phosphopeptide (figure 4g).In order to define the stoichiometry and dynamics of
phosphorylation at Ser45, it was important to co-evaluate the
singly and doubly phosphorylated peptides covering pSer45
and pSer42/45 (figure 4b–d ). Total pSer45 levels (pSer45*)
were calculated by summation of the percentage phosphoryl-
ation of the two pSer45-containing phosphopeptides for each
biological replicate (figure 4d). Although the singly phos-
phorylated pSer45-containing peptide peaked 5 min after
TNFa stimulation, subsequently rising again at later time
points (figure 4b), there was a consistent delay in pSer42/45
phosphopeptide dynamics, as determined by SRM (and
validated by western blotting), indicating that Ser45 phos-
phorylation occurs first. Indeed, Ser42 was never observed in
its phosphorylated form in the absence of pSer45 under these
conditions. Phosphorylation of Ser45 (pSer45*, figure 4d )
clearly demonstrates cyclical dynamics, with phosphoryla-
tion peaking rapidly after stimulation (approx. 5–10 min)
before decreasing to basal levels (20 min) and then rising to
maximal values after 40–60 min. Interestingly, this is similar
in timing to the dynamics observed for the pSer276-containing
peptide (figure 4e), a phosphorylation site previously demon-
strated to be essential for transcription from a subset of
NF-kB-dependent genes, exemplified by IL-8 transcription
[36,39,56,57].
The biological variance in phosphosite dynamics identified
between our biological replicates can be explained, in large
part, by the discrete rather than by continuous time-points
employed in our assays: note the much faster initial rate of
pSer42/45 for a single bioreplicate (figure 4c, black) which
consequently shifts the cycling phosphorylation levels earlier.
Perhaps unsurprisingly, the precise stoichiometry of phos-
phorylation at each time point is not identical for the
individual bioreplicate samples, suggesting that it is the vari-
ation or fold-change in levels of a given phosphorylation site
that mediates stimulation-induced responses rather than the
absolute stoichiometry of modification.2.5. Rapid RelA phosphorylation at Ser42/45 regulates
DNA binding and transcription
As a consequence of our molecular modelling, we hypoth-
esized that phosphorylation of Ser42 and/or Ser45 regulates
the interaction of RelAwith kB DNA and RelA transcriptional
activity. To examine potential roles for Ser42 and Ser45, both
phosphomimetic (Ser! Asp) and phosphonull (Ser! Ala)
mutants of RelA were assessed for their effect on RelA
nuclear mobility (figure 5) and DNA binding (figure 6).
Fluorescent recovery after photobleaching (FRAP; figure 5a)
was used to evaluate the nuclear mobility of RelA, under the
hypothesis that differential DNA binding of the RelA protein
variants would alter their diffusion rates. The recovery of fluor-
escent signal of RelA–DsRed after photobleaching is much
slower for protein that is anchored to DNA (figure 5b,c); this
assay is arguably of greater physiological relevance in evaluat-
ing the effect of modification of specific residues when
compared with in vitro electromobility shift assay (EMSA).
We observed no significant difference in the half time to recov-
ery of any of the RelA–DsRed mutants from that of the
wild-type (WT) protein in the cytoplasm of non-stimulated
cells (figure 5d), as would be expected. However, there was a
statistically significant difference in the nuclear dynamics of
Ser42Asp and Ser45Asp mutants compared with WT in
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Figure 4. Selected-reaction monitoring (SRM) of RelA phosphorylation in response to treatment of SK-N-AS cells with the cytokine TNFa. (a) List of targeted
( phospho)peptides included in the SRM analysis. Sequences of peptides, including phosphorylation sites ( p), are listed along with their respective precursor
ion m/z values, precursor ion charge state, retention time (RT) and product ions. C represents carbamidomethylated cysteine; 298 indicates loss of H3PO4
from the precursor ion; 2116 indicates loss of (H3PO4 þ H2O) from precursor ion; n.d. not detected; consistently observed product ions are highlighted in
bold. (Phospho)peptides containing modified residues pSer45 (b), pSer42/45 (c), pSer45* (d ), pSer276 (e) and the RelA control peptide DGFYEAELCPDR, where
C denotes carbamidomethylation of Cys ( f ) were quantified by scheduled LC–SRM analysis following stimulation of SK-N-AS cells with TNFa; stimulation and
analysis was repeated in triplicate for three different biological replicates represented in black, blue and red. Isotope-labelled internal reference ( phospho)peptides
were included, permitting absolute peptide quantification and phosphorylation site stoichiometry determination. pSer45* is the calculated stoichiometry of the Ser45
phosphorylation site obtained by summating percentage phosphorylation of the pSer45 and pSer42/45 phosphopeptides. Immunoblot analysis of pSer42/45 (g) is
shown as a function of time following TNFa stimulation with reference to total RelA levels and actin control.
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Ser42/45 phosphomimetics recovered much faster (lower thalf )
than that of WT protein after photobleaching, indicative of
increased mobility of these two proteins under conditions
where RelA is transcriptionally active and is thus expected tobind DNA. These data are in agreement with a significant
decrease in DNA binding arising owing to phosphorylation
at Ser42 or Ser45. As a control, recovery of fluorescent signal
(a proxy for mobility) was also determined for a Tyr36Ala/
Glu39Asp RelA non-DNA binding mutant (NBM) [47],
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Figure 5. Nuclear movement of S42/S45 phosphomimetic versions of RelA–DsRed is increased. Fluorescent recovery after photobleaching (FRAP) was used to assess
nuclear movement of RelA–DsRed species (wild-type (WT), S42A, S42D, S45A, S45D) in SK-N-AS cells. Cells were unstimulated (control) or stimulated with TNFa
(10 ng ml21) for 30 min prior to bleaching of a 3.14 mm2 (2 mm diameter) region of interest (ROI). (a) Single captures of a representative SK-N-AS cell nucleus
with WT RelA–DsRed: prior to bleaching and at 0, 5 and 10 s post-bleaching. Images show recovery of fluorescence into the ROI following bleaching. (b,c) Mean
fluorescent recovery curves of WT, S42A/S42D (b) and S45A/S45D (c) RelA–DsRed species. Error bars represent standard deviation (s). All curves are significantly
different from one another ( p, 0.0001). (d,e) Scatter dot plots of the half time to recovery, thalf (s), of individual RelA–dsRed species in the cytoplasm of
unstimulated cells (d ) or in the nucleus following TNFa treatment (e). NBM refers to the non-binding mutant (Y36A/E39D) of RelA. The Kruskal–Wallis test
was used with a Dunn’s multiple comparison test to determine statistical difference: *p, 0.1; ****p, 0.0001.
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Ser45Asp (data not shown). Like the Ser42Ala/Ser45Ala pro-
teins, the NBM only demonstrated a difference in mobility
following TNFa stimulation. These data confirm an inhibitory
effect of Ser42/45 phosphorylation on DNA binding, as pre-
dicted from our modelling. Interestingly, Ser42Ala–DsRed
exhibited a small but statistically significant ( p, 0.1) decrease
in thalf after TNFa stimulation, suggesting a minor decrease in
the ability of this mutant to remain anchored to chromatin.
This may potentially be explained by the decreased capabili-
ties of Ala compared with Ser to form hydrogen bonds with
the DNA backbone [58].
To validate the roles of these RelA phosphorylation sites on
cellular DNA binding in a more direct manner, chromatin
immunoprecipitation (ChIP) studies were performed using
either the IL-6 promoter (containing a single kB binding
site—TGGGATTTTCCCA [59]) or the IkBa promoter (contain-
ing three distinct kB binding sites—GAGAAAGTCCCC,
GGAAATTCCCC, GGGAAACC CC [60]) in SK-N-AS cells
transfected with either WT RelA, Ser42 or Ser45 phosphonull
or Ser42 or Ser45 phosphomimetic mutants (figure 6a).
Owing to the presence of endogenous RelA in these ChIP
assays, interpretation of these data has to consider co-
precipitation of both endogenous and transfected RelA
protein. In control cells, where endogenous RelAwas expected
to be largely unmodified at Ser42/45 (calculated as less than20%, figure 4), there was a statistically significantly increase
(2.9-fold) in IL-6 promoter binding of total RelA (endogenous
and overexpressed) in cells transfected with Ser42Ala. No stat-
istical difference was detected in RelA binding in cells
expressing Ser45Ala RelA at this promoter region. As expected
for conditions where RelA DNA binding was low, there was
also no statistical difference in DNA binding in cells expressing
the phosphomimetic mutants compared with those expressing
WT RelA. In marked contrast, there was no difference in the
binding of RelA from cells expressing Ser42Ala to the IkBa
promoter, although increased binding of RelA to this
promoter was observed in cells expressing the phosphonull
Ser45Ala protein, suggesting a differential role for these two
residues in mediating promoter-specific interactions.
Following cellular treatment with TNFa, where cells are
undergoing active kB-mediated transcription, we confirmed
enhanced DNA binding of RelA in the both the control and
WTRelA transfected cells to both promoter sequences. Perhaps
surprisingly, this stimulation-enhanced DNA binding of RelA
was ablated at both promoter sequences upon transfection
with the Ser42Ala RelA mutant. Indeed, there is a significant
decrease in RelA binding following transfection of Ser42Ala
upon stimulation, suggesting a dominant negative effect
of Ser42Ala RelA under these conditions. Overexpression of
Ser45Ala promotes a statistically significant increase in binding
of RelA to the IkBa promoter, an effect not observed for the
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Figure 6. Ser42 and Ser45 regulate DNA binding and transcription. (a,b) SK-N-AS cells were either untransfected (control, black) or transfected with wild-type (WT)
or mutant full-length RelA expression constructs. After 48 h, cells were treated with TNFa (5 ng ml21 for 3 h) prior to cross-linking of chromatin and cell harvest-
ing. Relative binding of RelA to the IL-6 (a) or IkBa (b) promoter was assessed by quantitative ChIP assay. (c) SK-N-AS cells were transfected with IL-6 promoter
luciferase construct and co-transfected with WT or mutant full-length RelA as indicated. Cells were harvested after 48 h and luciferase assay carried out on cell
lysates. Results are normalized to protein concentration; n ¼ 3. A one-way analysis of variance (ANOVA) with a post hoc Tukey multiple comparisons test was used
to probe for statistical differences: *p, 0.05, **p , 0.01, ***p, 0.001, ****p, 0.0001.
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these two residues on promoter-specific binding.
To investigate the regulatory effects of phosphorylation at
either of these two serine residues on transcription, SK-N-AS
cells were transfected with an IL-6-promoter–luciferase repor-
ter construct together with expression vectors for WT RelA,
the single or double phosphonull or phosphomimetic mutants,
or the known transcriptionally deficient Ser276Ala [39] RelA
expression construct (figure 6c). Expression of the Ser42 and/
or Ser45 phosphomimetics (S42D, S45D, S42D/45D) signifi-
cantly repressed transcription from the IL-6 promoter, akin to
that observed for Ser276Ala, when compared with the RelA
phosphonull variants (S42A, S45A, S45A/S45A). However,
no significant difference was observed between the two sites
(Ser42 or Ser45) in terms of relative luciferase reporter activity,
suggesting that phosphorylation at these sites may be partially
redundant, at least in the context of the IL-6 promoter. These
data therefore validate our hypothesis that phosphoryla-
tion of Ser42 and Ser45 abrogates DNA binding, consequently
negatively impacting transcription.
A one-way analysis of variance (ANOVA) with a post hoc
Tukey’s multiple comparisons test was used to probe for
statistical differences: *p, 0.05, **p, 0.01, ***p, 0.001 and
****p, 0.0001.3. Discussion
In this study, we identified multiple novel phosphorylation
sites on RelA, validating seven novel in cellulo phosphosites—
Ser42, Ser131, Thr136, Ser238 (data not shown), Ser261,
Ser269 and Ser472, and confirming Ser45 as a bona fide cellular
site of regulated phosphorylation.
To the best of our knowledge, this is the most extensive,
unbiased phosphosite analysis of an NF-kB transcription
factor familymember. For the first time, we have demonstrated
distinct stimulation-induced temporal regulation of a number
of phosphorylation events, and directly quantified the stoichi-
ometry of TNFa-induced phosphorylation as a function of time
for Ser42, Ser45 and Ser276 sites. Interestingly, the relative
phosphorylation of many of these sites by purified protein
kinases in vitrowas dependent on the conditions for dimeriza-
tion employed; modification of most sites was enhanced in the
presence of the RelA heterodimerization partner p50, although
PKA-mediated phosphorylation of Ser45 and Ser238, and
IKKb-mediated Thr136 phosphorylation were more efficient
for RelA homodimers. Furthermore, with the exception of
Ser42/45, phosphorylation was perturbed upon addition of
IkBa, providing evidence for protein complex-specific effects
on phosphorylation.
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evaluated by bioinformatic and structural analysis, and new
roles in regulating DNA binding predicted specifically for
Ser42 and Ser45. In agreement with our hypothesis, Ser42
and Ser45 phosphomimetic versions of RelA exhibited
increased nuclear mobility demonstrating decreased DNA
anchoring, similar to that observed for the previously
described RelA NBM (figure 5). Furthermore, the differential
binding of RelA observed by ChIP upon transfection of the
Ser42 and Ser45 mutants to either the IL-6 or IkBa promoters
indicates a complex role for modification of these two residues
in regulating promoter-specific interactions (figure 6). Based on
a luciferase reporter assay, the inability to phosphorylate either
or both of these residues promotes transcription from the IL-6
promoter, whereas RelA variants that mimic phosphorylation
at Ser42 and/or Ser45 repress transcription from the same pro-
moter. Interestingly, phosphorylation at Ser45 rather than at
Ser42 appears to preferentially regulate binding to the IkBa
promoter with a statistically significant increase in binding of
the phosphonull Ser45Ala RelA. Curiously, Ser42Ala exhibits
unexpected behaviour with respect to DNA binding at both
promoters following cellular stimulation with TNFa. This
may be owing to differential binding of other transcription
factors to Ser42Ala, or potentially that Ser45 can still be phos-
phorylated in this Ser42Ala variant. These remain avenues
for further exploration. It is interesting to note that in vitro phos-
phorylation of Ser45 by IKKb (but not PKA) is significantly
enhanced by p50, suggesting that this is heterodimer-specific
phosphorylation event. The notable increase in phosphoryl-
ation at Ser42 and Ser45 upon inclusion of IkBa in the in vitro
assay, and the close proximity of these two residues to the inter-
face of RelAwith IkB suggests a conformational change in this
region that increases residue accessibility upon IkB binding. It
will thus be interesting to evaluate the effect of modification of
these sites on the conformation and interactome of RelA.
The dynamics of Ser42/45 phosphorylation is consistent
with a model that modification of one or both of these
residues serves to directly regulate RelA-mediated transcrip-
tion by disrupting association with the kB promoter on
DNA. For example, rapid phosphorylation 5 min after TNF
exposure probably inhibits the function of RelA already loca-
lized to the nucleus, whereas the latter peak in pSer42/45
might act to prevent transcriptional activity after TNFa-
induced RelA nuclear translocation. That pSer42 is never
observed in the absence of pSer45 in response to this stimu-
lus suggests that these residues may work together in a
concerted ‘belt and braces’ mechanism to efficiently regulate
DNA binding.
More generally, our in vitro kinase assays suggest a p50-
induced change in the structure of RelA that facilitates its
hyperphosphorylation. Abrogation of a number of these phos-
phorylation sites, particularly those localized to the C-terminal
region of the RHD upon inclusion of IkBa, under conditions
where native (inhibitor bound) RelA : p50 heterodimer is pre-
sent, suggests either a masking effect by IkB on the otherwise
available phosphorylation sites on RelA, or (more likely) a
structural change in the heterodimer upon IkB binding which
reduces accessibility of this region of the RHD. More generally,
our data support the idea that different RelA dimers are prob-
ably subject to differential regulation and functional
modulation.
Taken together, our biochemical, structural and cellular
evaluation of RelA provides compelling evidence for a dynamicpool of post-translationallymodified (primarily phosphorylated)
proteoforms of RelA, which are rapidly and dynamically regu-
lated in response to an extracellular stimulus (TNFa). The high
complexity of the RelA phosphorylation patterning increases
the likelihood of distinct combinations, or fingerprints, of protein
modification (sometimes referred to as the NF-kB barcode
hypothesis) [9,32] as one key for the formation of transcriptional
complexes that support differential transcriptional output.While
these studies focused primarily on phosphorylation of RelA at
Ser42 and Ser45, it will be interesting to assess the dynamics of
modification of these (and other) sites under different cellular
conditions, with the ultimate view of identifying different RelA
‘codes’ or proteoforms that engage distinct promoters.
The inherent problems with ‘bottom-up’ peptide-based
proteomics analyses are particularly acute for the comprehen-
sive investigation of RelA (and other NF-kB) proteoforms. The
analysis of the intact RelA protein by top-down proteomics
[61,62] will therefore be particularly powerful when used in
conjunction with our bottom-up discovery and targeted
quantification strategies. The first top-down investigation
using an overexpressedHalo-tagged form of RelA has recently
been reported [63], although the myriad of phosphoforms that
we know are present were not annotated, probably owing to
the inherent difficulties of working on low abundance,
highly modified protein species the size of RelA. Our new
platform for RelA analysis should rapidly permit unique
‘NF-kB fingerprints’ and their functional relationships with
promoter-specific transcription to be assessed.
4. Methods
4.1. Cell culture and lysis
SK-N-AS cells were grown in RPMI medium to 80% conflu-
ence and stimulated with TNFa (10 ng ml21; Calbiochem)
for up to 60 min. Growth medium was removed, and cells
washed three times with PBS. Cells were lysed on ice by
addition of lysis buffer (25 mM Tris–HCl pH 8, 0.15 M
NaCl, 0.1% (v/v) NP-40, 1 mM EDTA, 1 mM EGTA, 10 mM
b-glycerophosphate, 10 mM NaF, 300 mM Na3VO4, 1 mM
benzamidine, 2 mM PMSF, mini EDTA-free protease inhibitor
cocktail tablet and 1 mM DTT). Lysates were cleared by
centrifugation (14 000g, 10 min, 48C) and supernatants har-
vested. For the cross-linking IP experiments, the lysis buffer
was modified to include 0.25% (v/v) Triton X-100 instead
of 0.1% (v/v) NP-40 and 500 mM NaCl.
4.2. Immunoprecipitation of RelA using antibody cross-
linked magnetic protein G beads
Cell lysates were pre-cleared by incubation with 20 ml of
protein G beads (48C for 10 min) followed by centrifugation
(14 000g, 48C, 1 min). RelA antibody (sc372, Santa Cruz
Biotechnology; 2 mg) was cross-linked to magnetic protein G
beads (20 ml) using the cross-linking magnetic IP kit (Pierce,
USA) according to the manufacturer’s instructions (see elec-
tronic supplementary material, Methods for full details). Cell
lysate (500 mg) was added to the antibody-cross-linked beads
and incubated for 1 h at room temperature. Unbound material
was collected using a magnetic stand, beads were washed
twice with 200 ml of lysis buffer, twice with 200 ml of IP
buffer (40 mM Tris–HCl pH 8, 0.1% (v/v) NP-40, 1 mM
EGTA, 6 mM EDTA, 6 mM DTT, 0.5 M NaCl, 1 mM
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PMSF, 300 mM Na3VO4, mini EDTA-free protease inhibitor
cocktail), once with 500 ml of HPLC water and three times
with 500 ml of 25 mM NH4HCO3 pH 8. Beads were resus-
pended in 160 ml of 25 mM NH4HCO3, to which 10 ml of a
1% (w/v) solution of RapiGest SF [64] (Waters, UK) in
25 mM NH4HCO3 was added. Samples were heated at 968C
for 10 min, and supernatants containing the eluted RelA were
recovered using a magnetic stand and used for in-solution
digestion.
4.3. In vitro kinase assays
Purified truncated RelA (12–317; 5 mg [65]) was incubated
with IKKa or PKA (Invitrogen, UK) in kinase buffer
(25 mM Tris–HCl pH 7.5, 10 mM MgCl2, 0.5 mM EGTA,
2.5 mM DTT and 200 mM ATP) for 2 h at 378C, 50 ml total
volume. Assays were also performed with equimolar concen-
trations of p50 (35–381) [65], with or without equimolar
GST-IkBa (59981, Abcam, UK). Phosphorylated proteins
were diluted to 0.1 mg ml21 in 50 mMNH4HCO3 and prepared
for digestion.
4.4. Sample preparation for LC–MS/MS analysis
Disulfide bonds were reduced by addition of DTT (4.2 mM,
608C, 10 min) and free Cys alkylated with iodoacetamide
(IOA; 16 mM, dark, RT, 30 min). DTT was added to a final
concentration of 8 mM and proteins digested by addition of
trypsin (0.2 mg ml21 in 10 mM AcOH, O/N, 378C) to 2%
(w/w). Digestion was stopped by addition of 5.5 ml 100%
AcN and RapiGest SF hydrolysis induced with neat TFA
(2.5 ml). Samples were incubated (378C for up to 2 h,
400 r.p.m.) until a white precipitate was observed and then
for a further 2 h at 48C for 2 h. Insoluble hydrolysis product
was removed by centrifugation (13 000g, 15 min, 48C). Diges-
tion was also performed without reduction and alkylation to
preserve oxidative modifications of cysteine residues.
4.5. TiO2 enrichment of phosphorylated peptides
Digests were dried by centrifugal evaporation (10 ml) and reso-
lubilized in loading buffer (65% (v/v) AcN, 2% (v/v) TFA,
saturated with glutamic acid, 200 ml). Phosphopeptides were
enriched using 200 ml pre-packed TiO2 spin tips (ProteaBio,
France) [66]. Unbound peptides were dried by centrifugal
evaporation, re-suspended in 20 ml of 0.1% (v/v) TFA and
desalted using C18 Zip Tips (Millipore, USA). The eluates
were dried as above, resolubilized in 200 ml of 2% (v/v)
AcN, 0.1% (v/v) FA and dried again. After repeating the resus-
pension and drying, peptides were stored at 2208C for nano
LC–ESI–MS/MS analysis.
4.6. Data-dependent nano LC–ESI–MS/MS
nLC–ESI–MS/MS analyses were performed on a Bruker
amaZon ETD ion trapTM arranged in-line with an Ultimate
3000 nanoflow uHPLC systemTM (Thermo Scientific, USA).
Peptides were directly eluted over a 35 min LC gradient and
a full scan mass spectrum acquired over m/z 300–1800, with
the three most abundant ions being selected for isolation and
activation with either CID and/or ETD (alternating). Peaklists
from both the CID and ETD MS/MS spectra were extractedusing DATA ANALYSIS software v. 4.0 (Bruker, Germany) and
converted into mascot generic files (.mgf). .mgf files were
searched against the concatenated SwissProt database
(2011.05.03) and decoy using Mascot (v. 2.2.06), specifying H.
sapiens for taxonomy. Parameterswere set as follows: precursor
mass tolerance at 0.4 Da; product ion tolerance at 0.6 Da; less
than or equal to one missed cleavage; fixed modification: car-
bamidomethyl Cys; variable modifications: deamidation of
Asn and Gln, oxidation of Met, phosphorylation of Ser, Thr
and Tyr. Top-ranking peptide matches in Mascot were using
ion score greater than or equal to 25 and an expectation value
of less than or equal to 0.1. False-discovery rates at the protein
and peptide level were assessed by searching against the decoy
database (max. 1%). All CID and ETD tandem mass spectra of
phosphorylated peptides were manually inspected.
4.7. Quantification of protein phosphorylation by
selected reaction monitoring
Transitions for SRM were defined either using experimentally
observed precursor and product ionm/z values of RelA (phos-
pho)peptides, or SKYLINE (v. 1.2) [67] where this information
was unavailable. All samples were analysed by nano
uHPLC-SRM–MS/MS using a nanoACQUITY UPLCTM
system in-line with a Xevo TQ MS (Waters, UK). Transition
lists were divided to achieve a minimum dwell time of 50 ms
per transition. Each peptide was defined by six transitions,
including neutral loss of H3PO4 and (H3PO4 þ H2O) for the
phosphorylated peptides. Chromatographic traces of the tran-
sitions were manually inspected using SKYLINE (v. 1.2).
A peptide was considered as positively identified when at
least two co-eluting transitions could be observed.When avail-
able, retention times and relative abundance of product ions of
in vitro generated RelA phosphopeptides were used as an
additional filter. The most intense chromatographic peak of n
co-eluting transitions for a single peptide (n ¼ from 2 to 6)
was classified as ‘top rank’ and its peak area value extracted.
4.8. Generation of pSer42/45 antibody
Phosphopeptide (and dephosphopeptide for purification) was
synthesized corresponding to residues 38–50 (CEGRpSAGp-
SIPGER) where p indicates the sites of phosphorylation at
Ser42 and Ser45. The phosphopeptide was used to generate a
novel custom rabbit polyclonal antibody (Eurogentec).
4.9. Sequence alignment and interface analysis
RelA sequences were aligned usingMUSCLE [26], and the con-
servation of phosphorylation sites was manually determined.
Structural files containing RelAwere recovered from the Protein
Data Bank and protein : protein interfaces identified using
Protein interfaces, surfaces and assemblies service (PISA;
http://www.ebi.ac.uk/pdbe/prot_int/pistart.html [68]). Inter-
faces predicted to be the result of crystal artefacts were not
analysed.
4.10. Fluorescence recovery after photobleaching
Cells were transfected using FuGENE HD (Promega) with
RelA–dsRed-Express (dsRedxp) species and seeded in 2 ml
of MEM (100 000 cells ml21) in 35 mm single and four
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Ziess XL incubator (378C, 5% CO2). TNFa (10 ng ml
21) was
added for 30 min to allow for a maximal first translocation
prior to performing the FRAP analysis for the following
15 min. Images were collected using a Zeiss LSM 710 confo-
cal microscope. dsRedXP was excited using 561 nm diode
laser light, the resultant fluorescent emissions were collected
between 580 and 630 nm, defining a 3.14 mm2 region of
interest in the nucleus. Relative fluorescent intensity was
normalized to the pre-bleached plateau with 100% corre-
sponding to the highest recorded fluorescent intensity of a
given cell and 0% corresponding to an absence of fluorescent
signal. A ‘one-phase association, nonlinear regression’ curve
([Y ¼ Y0 þ (plateau – Y0)  (12 exp(2K  x))], where Y0 is
the y-value when x is zero, plateau is the Y value at infinite
times and K is the rate constant) was fitted to the FRAP recov-
ery curves; traces with an R2 value less than 0.7 were
removed from the dataset. The derived rate constant (K )
was used as a measure of nuclear mobility.
4.11. Cell transfection and chromatin
immunoprecipitation assay
SK-N-AS cells were transfected in duplicate with 1 mg
DsRed empty vector (control) or DsRed-RelA WT or mutant
(including S42A, S42D, S45A, S45D) vectors using Effectene
transfection reagent as per manufacturer’s instructions
(Qiagen). Cells were then grown for 48 h; one half of the dupli-
cate cultures were treated with 5 ng ml21 TNFa for 3 h and
fixed in 1% formaldehyde, harvested by scraping into PBS
with protease inhibitors and cell pellets resolubilized in lysis
buffer (1% SDS, 10 mM EDTA, 50 mM Tris–HCl (pH 8.0))
for 30 min, then sonicated for 10 cycles (30 s on, 20 s off) in
Diagenode Bioruptor. The sonicated samples were centrifuged
(13 000 r.p.m., 48C, 10 min), the cleared supernatant collected
and chromatin contentmeasured based onOD260 nm.Chroma-
tin immunoprecipitation (ChIP) assays were carried out using
50 mg cross-linked pre-cleared chromatin which was incubated
with 5 mg anti-RelA or control antibodies; the complexes were
precipitated, washed and eluted. Cross-links were reversed
and genomic DNA purified. Each PCR was performed in
duplicate and the analysis repeated at least three times fromindependent ChIP experiments. A signal intensity value for
each sample was calculated from the average of the exper-
iments. Average values of eluates were normalized to
average values of the control antibody sample and expressed
as fold enrichment above background (i.e. control antibody).
Quantitative PCR amplification was carried out using primers
that encompass RelA binding site(s) within the human IL-6 or
IkBa promoters (sequences available on request).4.12. Luciferase reporter assay
SK-N-AS cells were transfected in triplicate with 100 ng of
Renilla luciferase vector (pRLTK, transfection efficiency con-
trol, Promega), 0.5 mg IL-6 promoter–luciferase reporter
(pIL6-Lux) and 1 mg RelA expression constructs, either WT
or mutant (S42A, S42D, S45A, S45D, S42A/S45A, S42D/
S45S, S276A, using Effectene transfection reagent as per the
manufacturer’s instructions (Qiagen). Luciferase assays were
performed using a dual luciferase kit (Promega) according
to the manufacturer’s instructions. IL-6 promoter-driven
expression of firefly luciferase was normalized for differences
in transfection efficiency by measurement of the activity of
the co-transfected Renilla luciferase vector (pRLTK). In
brief, 48 h post-transfection cells were harvested into passive
lysis buffer (part of dual luciferase kit). The firefly luciferase
reagent (100 ml; LARII) was added to the test sample, with a
10 s equilibration time and measurement of luminescence
with a 10 s integration time, followed by addition of 100 ml of
the Renilla luciferase reagent and firefly quenching (Stop &
Glo), 10 s equilibration time, and measurement of luminescence
with a 10 s integration time. The data are represented as the
ratio of firefly to Renilla luciferase activity (Fluc/Rluc).Competing interests. We declare we have no competing interests.
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